Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 8, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08

Reporting Person: GELLERT MICHAEL E (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	145921	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (281293)		Direct
Series B Preferred Stock	$		Common Stock (255721)		Direct
Series C Preferred Stock	$		Common Stock (261054)		Direct

Footnotes

F1: The Series A, Series B and Series C Preferred Stock are convertible into Common Stock on a 2.133-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.